{"nctId":"NCT01666808","briefTitle":"FACBC Outcomes for Post Prostatectomy","startDateStruct":{"date":"2012-09","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":165,"armGroups":[{"label":"FACBC PET scan","type":"EXPERIMENTAL","interventionNames":["Drug: FACBC"]},{"label":"Conventional-Only Imaging","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: Radiation therapy"]}],"interventions":[{"name":"FACBC","otherNames":["anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid"]},{"name":"Radiation therapy","otherNames":["Intensity-modulated radiotherapy (IMRT)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adenocarcinoma of the prostate, post radical-prostatectomy Detectable PSA\n* ECOG/Zubrod Performance Status of 0-2\n* Negative technetium 99-m MDP or F-18 PET bone scan for skeletal metastasis\n* CT or MR scan of abdomen and pelvis which does not suggest presence of metastatic disease outside of the pelvis\n* Willingness to undergo pelvic radiotherapy.\n\nExclusion Criteria:\n\n* Contraindications to radiotherapy (including active inflammatory bowel disease or prior pelvic XRT)\n* Inability to undergo anti-3-\\[18F\\]FACBC PET-CT\n* Age under 18\n* Metastatic disease outside of pelvis on any imaging or biopsy\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years\n* Severe acute co-morbidity, defined as follows:\n\n  * Unstable angina and/or congestive heart failure requiring hospitalization in the last 3 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\n  * Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immunocompromised patients","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"95 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Failure-free Survival","description":"Definition of failure is: serum PSA value of 0.2ng/mL or more above the postradiotherapy nadir followed by another higher value, a continued rise in the serum PSA despite radiotherapy (RT), initiation of systemic therapy after completion of RT, or clinical progression.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"63.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Decision Changes Regarding Radiotherapy Versus no Radiotherapy","description":"Number of decision changes regarding radiotherapy versus no radiotherapy based on F-Fluciclovine PET/CT guidance. This outcome was assessed immediately after the consensus reading of the Fluciclovine PET/CT was completed by nuclear medicine, an average of 1 week post intervention.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Decision Changes Regarding Whole-pelvis Versus Local Fields","description":"Number of decision changes regarding whole-pelvis versus local fields. This outcome was assessed immediately after the consensus reading of the Fluciclovine PET/CT was completed by nuclear medicine, an average of 1 week post intervention.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Decision Changes","description":"Total number of radiotherapy decision changes regarding radiotherapy vs no radiotherapy and regarding whole pelvis vs local fields. This outcome was assessed immediately after the consensus reading of the Fluciclovine PET/CT was completed by nuclear medicine, an average of 1 week post intervention.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Prostate Bed Clinical Target Volume (CTV)","description":"Absolute volume pre- vs post-PET. This outcome was assessed after radiotherapy treatment planning was completed by radiation oncology, an average of 1 month post-intervention.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134.14","spread":"45.60"},{"groupId":"OG001","value":"137.18","spread":"51.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135.61","spread":"45.51"}]}]}]},{"type":"SECONDARY","title":"Prostate Bed Planning Target Volume (PTV)","description":"Absolute volume were measured pre- vs post-PET. This outcome was assessed after radiotherapy treatment planning was completed by radiation oncology, an average of 1 month post-intervention.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"324.50","spread":"79.82"},{"groupId":"OG001","value":"327.71","spread":"88.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"329.54","spread":"81.34"}]}]}]},{"type":"SECONDARY","title":"PTV Dosimetric Endpoints","description":"Standard radiotherapy dosimetric endpoints used to evaluate target coverage. Planning target volume (PTV) at V100 and V110 refer to %volume of the structure receiving 100% and 110% of the prescription dose, respectively, pre and post positron emission tomography (PET). This outcome was assessed after radiotherapy treatment planning was completed by radiation oncology, an average of 1 month post-intervention.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.98","spread":"1.56"},{"groupId":"OG001","value":"96.36","spread":"1.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.62","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":"7.81"},{"groupId":"OG001","value":"0.42","spread":"1.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"6.11"}]}]}]},{"type":"SECONDARY","title":"Rectum Dosimetric Endpoints","description":"Standard radiotherapy dosimetric endpoints used to evaluate normal tissue doses, in this case, the rectum. V40 and V65 refer to the %volume of the structure receiving 40 Gy and 65 Gy, respectively, pre and post positron emission tomography (PET) volumes were compared. This outcome was assessed after radiotherapy treatment planning was completed by radiation oncology, an average of 1 month post-intervention.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.01","spread":"10"},{"groupId":"OG001","value":"45.03","spread":"10.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.07","spread":"9.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.35","spread":"7.78"},{"groupId":"OG001","value":"19.31","spread":"7.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.48","spread":"7.78"}]}]}]},{"type":"SECONDARY","title":"Bladder Dosimetric Endpoints","description":"Standard radiotherapy dosimetric endpoints are used to evaluate normal tissue doses, in this case, the bladder. V40 and V65 refer to the %volume of the structure receiving 40 Gy and 65 Gy, respectively, pre and post positron emission tomography (PET) volumes were compared. This outcome was assessed after radiotherapy treatment planning was completed by radiation oncology, an average of 1 month post-intervention.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.92","spread":"14.94"},{"groupId":"OG001","value":"68.95","spread":"18.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.10","spread":"14.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.68","spread":"17.31"},{"groupId":"OG001","value":"50.99","spread":"19.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.29","spread":"19.92"}]}]}]},{"type":"SECONDARY","title":"Rate of ≥ Grade 2 GU (Genitourinary [Renal or Urinary]) Toxicity","description":"Provider-reported maximum acute (\\<90 days Post-Intervention) and late (≥90 days and up to 3-Years post-intervention) genitourinary toxicity based on CTCAE v4.0 criteria.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of ≥ Grade 2 GI (Gastrointestinal) Toxicity","description":"Provider-reported maximum acute (\\<90 days Post-Intervention) and late (≥90 days and up to 3-Years post-intervention) gastrointestinal toxicity ≥ Grade 2 based on CTCAE v4.0 criteria.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC) GU (Genitourinary) Domain Score","description":"Patient-reported maximum genitourinary toxicity based on standard EPIC-CP questionnaire. EPIC GU domain score has a total score range 0-12. Higher score correlates with worse outcome. EPIC GU score includes the incontinence domain score and the irritative/obstructive.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.99","spread":"3.10"},{"groupId":"OG001","value":"3.50","spread":"3.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"2.02"},{"groupId":"OG001","value":"2.66","spread":"2.70"}]}]}]},{"type":"SECONDARY","title":"Expanded Prostate Cancer Index Composite (EPIC) GI (Gastrointestinal) Domain Score","description":"Patient-reported maximum gastrointestinal toxicity based on standard EPIC-CP questionnaire. Total score range 0-12. Higher score correlates with worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"1.99"},{"groupId":"OG001","value":"1.41","spread":"2.21"}]}]}]},{"type":"SECONDARY","title":"Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Score","description":"Patient-reported maximum sexual function toxicity based on standard EPIC-CP questionnaire. Total score range 0-12. Higher score correlates with worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.04","spread":"4.14"},{"groupId":"OG001","value":"7.37","spread":"3.79"}]}]}]},{"type":"SECONDARY","title":"Expanded Prostate Cancer Index Composite (EPIC) Total Score","description":"Patient-reported maximum overall (genitourinary, gastrointestinal, and sexual function) toxicity based on standard EPIC-CP questionnaire. Total score range 0-60. Higher score correlates with worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.90","spread":"9.98"},{"groupId":"OG001","value":"17.02","spread":"9.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":83},"commonTop":["Urinary Frequency","Diarrhea"]}}}